Board bloc still is pushing to divest the Rx segment, though it achieved 4% volume sales growth and $6m in new product sales in the second quarter. Apparent second-quarter validation isn't enough to persuade CEO John Hendrickson to stay on.
Perrigo Co. PLC isn’t making it easy for a bloc of board members to succeed in pushing to divest the firm’s Rx generic business. The company's finances are stabilizing despite challenges such as ongoing price erosion hammering the prescription generics sector.
The company's Aug. 10 earnings briefing was led by CEO John Hendrickson, who announced plans in June to step down...
The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.
Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
Series B cash will be used to advance its Stargardt disease gene therapy.
